Literature DB >> 29393702

Radiolabeled mAbs as Molecular Imaging and/or Therapy Agents Targeting PSMA.

Dimitrios Psimadas1, Varvara Valotassiou1, Sotiria Alexiou1, Ioannis Tsougos1, Panagiotis Georgoulias1.   

Abstract

Molecular imaging and therapy is a rapidly evolving field in research and clinical medicine. The use of the exciting and attractive properties of radioisotopes for imaging and therapy has made Nuclear Medicine very significant when it comes to molecular imaging/therapy. Monoclonal Antibodies (mAbs) on the other hand are very important targeting biomolecules with high affinity that can "carry" the radioisotope of choice. Herein we make a brief overview of the radiolabeled mAbs that target prostate specific membrane antigen (PSMA) and their use in the management of patients with prostate cancer (PCa).

Entities:  

Keywords:  Antibodies; PSMA; prostate cancer; radiolabeling

Mesh:

Substances:

Year:  2018        PMID: 29393702     DOI: 10.1080/07357907.2018.1430816

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  4 in total

Review 1.  Recent Advances in the Development of Tetrazine Ligation Tools for Pretargeted Nuclear Imaging.

Authors:  Rocío García-Vázquez; Umberto Maria Battisti; Matthias M Herth
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-30

2.  Ultrasmall Renally Clearable Silica Nanoparticles Target Prostate Cancer.

Authors:  Feng Chen; Kai Ma; Li Zhang; Brian Madajewski; Melik Z Turker; Fabio Gallazzi; Kiara Cruickshank; Xiuli Zhang; Pocharapong Jenjitranant; Karim A Touijer; Thomas P Quinn; Pat Zanzonico; Ulrich Wiesner; Michelle S Bradbury
Journal:  ACS Appl Mater Interfaces       Date:  2019-11-13       Impact factor: 9.229

3.  Image-Guided Surgery: Are We Getting the Most Out of Small-Molecule Prostate-Specific-Membrane-Antigen-Targeted Tracers?

Authors:  Albertus Wijnand Hensbergen; Danny M van Willigen; Florian van Beurden; Pim J van Leeuwen; Tessa Buckle; Margret Schottelius; Tobias Maurer; Hans-Jürgen Wester; Fijs W B van Leeuwen
Journal:  Bioconjug Chem       Date:  2020-01-06       Impact factor: 4.774

4.  A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile.

Authors:  Srikanth Boinapally; Hye-Hyun Ahn; Bei Cheng; Mary Brummet; Hwanhee Nam; Kathleen L Gabrielson; Sangeeta R Banerjee; Il Minn; Martin G Pomper
Journal:  Sci Rep       Date:  2021-03-29       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.